Viyash Scientific share news, announcements and annual reports
NSE: VIYASHBSE: 512529Pharmaceuticals & BiotechnologySmall Cap
Viyash Scientific Limited · Formerly Sequent Scientific · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Sep 1990 on BSE, Mar 2016 on NSE
Last close ₹218.39down ₹6.16 (2.74%)BSE ₹218.50
Share price at the NSE close on 30 Oct 2026. Previous close ₹224.55.
30 Oct: open ₹224.59, high ₹225.84, low ₹217.35
52-week range of traded prices to 30 Oct 2026
₹178.13Low, 23 Mar 2026₹298.00High, 6 Jul 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹9,645 Cr598th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Earlier quarters restated in the year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 3.31
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 11.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.14
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 11,13,10753.2% delivered
Viyash Scientific disputes and clarifications
24 filed, newest first.
Jul 2025
Jul 2024
11 Jul · Legal
Significant increase in volume has been observed in Sequent Scientific Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited.
May 2024
Apr 2024
29 Apr · Legal
Exchange has sought clarification from Sequent Scientific Limited with respect to announcement dated 10-Apr-2024, regarding providing guarantee and pledging of equity shares of its Indian Subsidiaries. On basis of above the Company is required to clarify following: a) name of party for which such guarantees or indemnity or surety was given; b) whether the promoter/ promoter group/ group companies have any interest in this transaction? If yes, nature of interest and details thereof and whether the same is done at arm's length; c) brief details of such guarantee or indemnity or becoming a surety viz. brief details of agreement entered (if any) including significant terms and conditions, including amount of guarantee; d) impact of such guarantees or indemnity or surety on listed entity. The response of the Company is awaited.
Nov 2023
29 Nov · Legal
The exchange asked on 28 Nov 2023
Sep 2023
15 Sep · Legal
Exchange has sought clarification from Sequent Scientific Limited with respect to announcement dated 14-Jul-2023, regarding discontinuation of operations at the Company's manufacturing unit located at Tarapur, Maharashtra. On basis of above the Company is required to clarify following: 1. Amount & percentage of turnover or revenue or income and net worth of the listed entity contributed by such unit or division during the last financial year; 2. Reasons for closure. The response of the Company is awaited.
May 2023
17 May · Legal
The exchange asked on 16 May 2023
Apr 2023
20 Apr · Legal
The exchange asked on 19 Apr 2023
Nov 2022
Aug 2022
25 Aug · Legal
Exchange has sought clarification from Sequent Scientific Limited with respect to announcement dated 09-May-2022 informing about Fire incident in wholly owned subsidiary's Unit at Ramky Pharma City SEZ JNPC, Visakhapatnam.On the basis of aforesaid announcement, the Company is required to provide/clarify the following:Disruption of operations due to natural calamity, force majeure or events such as strikes, lockouts etc (At the time of occurrence) 1. Expected quantum of loss/damage caused; 2. Whether loss/damage covered by insurance or not including amount; 3. Estimated impact on the production/operations in case of strikes/lock outs; Disruption of operations due to natural calamity, force majeure or events such as strikes, lockouts etc (Regularly, till complete normalcy is restored) 1. Insurance amount claimed and realized by the listed entity for the loss/damage; 2. The actual amount of damage caused due to the natural calamity or other force majeure events; 3. Details of steps taken to restore normalcy and the impact of the natural calamity/other force majeure events on production or service, financials of the entity The response of the company is awaited.
May 2022
24 May · Legal
The exchange asked on 23 May 2022
Dec 2021
10 Dec · Legal
The exchange asked on 9 Dec 2021
May 2020
22 May · Legal
Exchange has sought clarification from Sequent Scientific Limited for the quarter ended 31-Mar-2020 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. The company has not submitted the Statement of Modified Opinion or in case of unmodified opinion(s), a declaration to that effect to the Stock Exchange. The response of the Company is awaited.
Mar 2020
27 Mar · Legal
The exchange asked on 26 Mar 2020
Sep 2019
28 Sep · Legal
The exchange asked on 27 Sep 2019
Jul 2019
18 Jul · Legal
Exchange has sought clarification from Sequent Scientific Limited with respect to announcement dated 05-Jul-2019, regarding the Company has appointed and designated Mr. Tushar Mistry, Chief Financial Officer as Compliance Officer till the time the vacancy of Company Secretary is filled by the Company. On basis of above the Company is required to clarify following: 1. Date of appointment of Mr. Tushar Mistry. The response of the Company is awaited.
Jun 2019
13 Jun · Legal
Exchange has sought clarification from Sequent Scientific Limited with respect to announcement dated 14-May-2019, regarding Change in Auditors of the company.". On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment)The response of the Company is awaited.
Aug 2018
21 Aug · Legal
The exchange asked on 20 Aug 2018
Mar 2018
Feb 2018
27 Feb · Legal
Exchange has sought clarification from Sequent Scientific Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Board meeting notice not submitted. The response of the Company is awaited.